Prognostic Significance of ARID1A Expression Patterns Varies with Molecular Subtype in Advanced Gastric Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: AT-rich interactive domain 1A (ARID1A) is frequently mutated in gastric cancer (GC), especially Epstein-Barr virus (EBV)-associated and microsatellite instability high GC. The loss of ARID1A expression has been reported as a poor prognostic marker in GC. However, the relationships between ARID1A alteration and EBV-associated and microsatellite instability high GC, which are known to have a favorable prognosis, has hampered proper evaluation of the prognostic significance of ARID1A expression in GC. We aimed to analyze the true prognostic significance of ARID1A expression by correcting confounding variables. Methods: We evaluated the ARID1A expression in a large series (n=1,032) of advanced GC and analyzed the relationships between expression pattern and variable parameters, including clinicopathologic factors, key molecular features such as EBV-positivity, mismatch repair protein deficiency, and expression of p53 and several receptor tyrosine kinases including human epidermal growth factor receptor 2, epidermal growth factor receptor, and mesenchymal-epithelial transition factor. Survival analysis of the molecular subtypes was done according to the ARID1A expression patterns. Results: Loss of ARID1A expression was found in 52.5% (53/101) of mutL homolog 1 (MLH1)- deficient and 35.8% (24/67) of EBV-positive GCs, compared with only 9.6% (82/864) of the MLH1-proficient and EBV-negative group (p<0.001). The loss of ARID1A expression was associated only with MLH1 deficiency and EBV positivity. On survival analysis, the loss of ARID1A expression was associated with worse prognosis only in MLH1-proficient and EBV-negative GC. Multivariate analysis revealed that both loss of ARID1A and decreased ARID1A expression were independent worse prognostic factors in patients with advanced GC. Conclusions: Only in MLH1-proficient and EBV-negative GC, the loss of ARID1A expression is related to poorer prognosis.
Abstract
Background/Aims: AT-rich interactive domain 1A (ARID1A) is frequently mutated in gastric cancer (GC), especially Epstein-Barr virus (EBV)-associated and microsatellite instability high GC. The loss of ARID1A expression has been reported as a poor prognostic marker in GC. However, the relationships between ARID1A alteration and EBV-associated and microsatellite instability high GC, which are known to have a favorable prognosis, has hampered proper evaluation of the prognostic significance of ARID1A expression in GC. We aimed to analyze the true prognostic significance of ARID1A expression by correcting confounding variables. Methods: We evaluated the ARID1A expression in a large series (n=1,032) of advanced GC and analyzed the relationships between expression pattern and variable parameters, including clinicopathologic factors, key molecular features such as EBV-positivity, mismatch repair protein deficiency, and expression of p53 and several receptor tyrosine kinases including human epidermal growth factor receptor 2, epidermal growth factor receptor, and mesenchymal-epithelial transition factor. Survival analysis of the molecular subtypes was done according to the ARID1A expression patterns. Results: Loss of ARID1A expression was found in 52.5% (53/101) of mutL homolog 1 (MLH1)- deficient and 35.8% (24/67) of EBV-positive GCs, compared with only 9.6% (82/864) of the MLH1-proficient and EBV-negative group (p<0.001). The loss of ARID1A expression was associated only with MLH1 deficiency and EBV positivity. On survival analysis, the loss of ARID1A expression was associated with worse prognosis only in MLH1-proficient and EBV-negative GC. Multivariate analysis revealed that both loss of ARID1A and decreased ARID1A expression were independent worse prognostic factors in patients with advanced GC. Conclusions: Only in MLH1-proficient and EBV-negative GC, the loss of ARID1A expression is related to poorer prognosis.
참고문헌 (42)
- Dallas PB, "The human SWI-SNF complex protein p270 is an ARID family member with non-sequence-specific DNA binding activity", Mol Cell Biol, 20, pp.3137~3146 (2000)
- Wilson BG, "SWI", SNF nucleosome remodellers and cancer, 2011, pp.11, 481~492
- Nagl NG Jr, "The p270(ARID1A", SMARCF1)subunit of mammalian SWI, Cancer Res, pp.2005, 65[DOI]
- Alver BH, "The SWI", SNF chromatin remodelling complex is required for maintenance of lineage specific enhancers, 2017, pp.8, 14648~
- Mathur R, "ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice", Nat Genet, 49, pp.296~302 (2017)
- Wang Y, "The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type", J Pathol, 242, pp.371~383 (2017)
- Shen J, "ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors", Cancer Discov, 5, pp.752~767 (2015)
- Suryo Rahmanto Y, "Inactivating ARID1A tumor suppressor enhances TERT transcription and maintains telomere length in cancer cells", J Biol Chem, 291, pp.9690~9699 (2016)
- Jones S, "Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma", Science, 330, pp.228~231 (2010)
- Wiegand KC, "ARID1A mutations in endometriosis-associated ovarian carcinomas", N Engl J Med, 363, pp.1532~1543 (2010)
- Wang K, "Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer", Nat Genet, 43, pp.1219~1223 (2011)
- Zang ZJ, "Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes", Nat Genet, 44, pp.570~574 (2012)
- Wang DD, "Decreased expression of the ARID1A gene is associated with poor prognosis in primary gastric cancer", PLoS One, 7, pp.e40364~ (2012)
- Maeda D, "Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma", Int J Mol Sci, 11, pp.5120~5128 (2010)
- Zhang X, "Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers", PLoS One, 8, pp.e53931~ (2013)
- Abe H, "ARID1A expression loss in gastric cancer : pathway-dependent roles with and without Epstein-Barr virus infection and microsatellite instability", Virchows Arch, 461, pp.367~377 (2012)
- Wiegand KC, "ARID1A", BAF250a as a prognostic marker for gastric carcinoma : a study of 2 cohorts, 2014, pp.45, 1258~1268
- Kim YB, "Various ARID1A expression patterns and their clinical significance in gastric cancers", Hum Pathol, 49, pp.61~70 (2016)
- 김경주, "Loss of ARID1A Expression in Gastric Cancer: Correlation with Mismatch Repair Deficiency and Clinicopathologic Features", Journal of Gastric Cancer, 15(3), pp.201~208 (2015), 대한위암학회[DOI]
- Ibarrola-Villava M, "Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer", Oncotarget, 6, pp.26935~26945 (2015)
- Glückstein MI, "Comprehensive immunohistochemical study of the SWI", SNF complex expression status in gastric cancer reveals an adverse prognosis of SWI, Cancers(Basel), pp.2021, 13[DOI]
- Zhu YP, "Loss of ARID1A expression is associated with poor prognosis in patients with gastric cancer", Hum Pathol, 78, pp.28~35 (2018)
- Inada R, "ARID1A expression in gastric adenocarcinoma : clinicopathological significance and correlation with DNA mismatch repair status", World J Gastroenterol, 21, pp.2159~2168 (2015)
- Lee SY, "Loss of AT-rich interactive domain 1A expression in gastrointestinal malignancies", Oncology, 88, pp.234~240 (2015)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of gastric adenocarcinoma", Nature, 513, pp.202~209 (2014)
- Park CK, "Receptor tyrosine kinase amplified gastric cancer : clinicopathologic characteristics and proposed screening algorithm", Oncotarget, 7, pp.72099~72112 (2016)
- 배윤성, "Usefulness of Immunohistochemistry for Microsatellite Instability Screening in Gastric Cancer", Gut and Liver, 9(5), pp.629~635 (2015), 거트앤리버 소화기연관학회협의회
- Park JH, "Epstein-Barr virus positivity, not mismatch repair-deficiency, is a favorable risk factor for lymph node metastasis in submucosa-invasive early gastric cancer", Gastric Cancer, 19, pp.1041~1051 (2016)
- Kim KH, "SWI", SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2, 2015, pp.21, 1491~1496
- Hofmann M, "Assessment of a HER2scoring system for gastric cancer : results from a validation study", Histopathology, 52, pp.797~805 (2008)
- Kim H, "High microsatellite instability predicts good prognosis in intestinaltype gastric cancers", J Gastroenterol Hepatol, 26, pp.585~592 (2011)
- Shinozaki-Ushiku A, "Update on Epstein-Barr virus and gastric cancer(review)", Int J Oncol, 46, pp.1421~1434 (2015)
- Han N, "Loss of ARID1A expression is related to gastric cancer progression, Epstein-Barr virus infection, and mismatch repair deficiency", Appl Immunohistochem Mol Morphol, 24, pp.320~325 (2016)
- Hampel H, "Screening for the Lynch syndrome(hereditary nonpolyposis colorectal cancer)", N Engl J Med, 352, pp.1851~1860 (2005)
- Kane MF, "Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repairdefective human tumor cell lines", Cancer Res, 57, pp.808~811 (1997)
- Toyota M, "Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype", Cancer Res, 59, pp.5438~5442 (1999)
- Kim H, "Concerted promoter hypermethylation of hMLH1, p16INK4A, and E-cadherin in gastric carcinomas with microsatellite instability", J Pathol, 200, pp.23~31 (2003)
- Zhao J, "Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells", Cancer, 119, pp.304~312 (2013)
- Allo G, "ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas", Mod Pathol, 27, pp.255~261 (2014)
- Odnokoz O, "ARID1 proteins : from transcriptional and post-translational regulation to carcinogenesis and potential therapeutics", Epigenomics, 13, pp.809~823 (2021)
- Kase K, "ARID1A deficiency in EBV-positive gastric cancer is partially regulated by EBVencoded miRNAs, but not by DNA promotor hypermethylation", Carcinogenesis, 42, pp.21~30 (2021)